Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.
Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC
Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.
Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC
Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.
Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC
Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC
Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.
Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.